not an expert statistics person , but I’ve posted a link before that explains futility analysis.
—- as I understand it a statistician has some sort of calculation that spits out a probability (of success / failure) for the final endpoint based on what ever is seen at interim in first few patients , in this case proteinuria difference.
—- it’s normally for the company to decide what is the lowest probability they’ll accept before deciding if it’s futile or not to keep trial going.
—- this will only apply to proteinurya endpoint not gfr as the futility in March appears to be on protein only
—-/ despite some other posters claims this has absolutely zilch to do with p value in the usual sense
not an expert statistics person , but I’ve posted a link before...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.030(8.00%) |
Mkt cap ! $225.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.5¢ | 37.0¢ | $637.2K | 1.624M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16500 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 169113 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |